Similarly, two separate studies investigated the impact of metformin in women without diabetes with metastatic breast cancer (primarily ER/PR+, HER2− disease), and both concluded that combining metformin with standard chemotherapy did not improve survival compared to chemotherapy alone [115,141]. This evidence concerns the gene ERBB2 and diabetes mellitus.